Alyftrek 125 mg/50 mg/10 mg film-coated tablets
Sponsors
Vertex Pharmaceuticals Inc.
Conditions
Cystic Fibrosis
Phase 3
A Phase 3, Open-label Study Evaluating the Long‑term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older
RecruitingCTIS2022-503081-74-00
Start: 2023-09-05Target: 14Updated: 2025-10-06
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis
Active, not recruitingCTIS2024-514173-22-00
Start: 2023-02-28Target: 331Updated: 2025-10-09